Autonomix Medical Inc. Common Stock (AMIX)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a margin of safety. Autonomix does not fit that mold. It is a development-stage medical device company with no revenue in the filed figures. In fiscal Q1 2027, the quarter ended 2026-06-30, it reported a net loss of $2.7 million and diluted EPS of -$5.02. For FY2026, ended 2026-03-31, the net loss was $16.7 million and diluted EPS -$2.32. FY2025, ended 2025-03-31, and FY2024, ended 2024-03-31, were also losses: $11.4 million and $15.4 million. The Lynch category is none because it lost money in each of the last four years. That is not a growth trajectory; it is a cash-consuming research effort. TTM free cash flow is -$13.2 million, and the FairStock FCF yield is -452.7%, meaning cash burn is far larger than its $2.9 million market cap. At the 2026-10-13 close of $3.01, the FairStock P/B is 0.52, which might look cheap on book value, but book value can vanish through continued losses. Other FairStock measures agree: P/E -0.08, ROE -315.99%, ROCE -157.81%, Piotroski 2/9, Altman Z -21.47. The business has a potentially interesting catheter-based neural sensing platform for pancreatic cancer, chronic pain, hypertension, and cardiovascular conditions, but no commercial revenue or proven moat is shown. Growth optionality exists only if clinical and regulatory milestones succeed. Graham would demand evidence of earnings and assets; Buffett would ask for a durable competitive advantage. I see neither in these numbers, only a speculative microcap with extreme volatility, a 52-week range of $0.20 to $24.68, and a beta of -0.94.

In plain English: Autonomix Medical is an early-stage medical device company working on a catheter-based system to sense and treat nerve-related disorders such as pancreatic cancer and chronic pain. It has no reported revenue and has lost money every year, so the business looks very weak and unproven. Because there are no sales or profits, the stock price is not meaningfully cheap or expensive by normal business numbers; it looks speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2025-12-31) · fiscal Q2 2026 10-Q (period ended 2025-09-30) · fiscal Q1 2026 10-Q (period ended 2025-06-30) · FY2026 10-K (period ended 2026-03-31) · FY2025 10-K (period ended 2025-03-31) · FY2024 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer